13:35 INNOMAXX BIOTEC<00340> - Results Announcement INNOMAXX Biotechnology Group Limited announced on 21/04/2005: (stock code: 00340 ) Year end date: 31/12/2004 Currency: HKD Auditors' Report: Unqualified (Audited ) (Audited ) Last Current Corresponding Period Period from 01/01/2004 from 01/01/2003 to 31/12/2004 to 31/12/2003 Note ('000 ) ('000 ) Turnover : 242,459 18,109 Profit/(Loss) from Operations : (47,247) (29,583) Finance cost : (2,373) (3,379) Share of Profit/(Loss) of Associates : (28,065) (1,051) Share of Profit/(Loss) of Jointly Controlled Entities : N/A N/A Profit/(Loss) after Tax & MI : (86,215) (35,290) % Change over Last Period : N/A % EPS/(LPS)-Basic (in dollars) : (0.0392) (0.0215) -Diluted (in dollars) : N/A N/A Extraordinary (ETD) Gain/(Loss) : N/A N/A Profit/(Loss) after ETD Items : (86,215) (35,290) Final Dividend : NIL NIL per Share (Specify if with other : N/A N/A options) B/C Dates for Final Dividend : N/A Payable Date : N/A B/C Dates for Annual General Meeting : 27/05/2005 to 30/05/2005 bdi. Other Distribution for : N/A Current Period B/C Dates for Other Distribution : N/A Remarks: 1. TURNOVER 2004 2003 HK$'000 HK$'000 Turnover represents the net amounts received and receivable for: Trading of pharmaceutical ingredients 163,730 - Trading of investments in securities 58,179 - Processing, storage and enrolment fees 11,724 9,287 Rental income 8,805 8,807 Dividend income from investments in securities 21 1 Other investment income - 14 ----------------------- 242,459 18,109 ======================= 2. LOSS PER SHARE The calculation of the loss per share is based on the net loss for the year of approximately HK$86,215,000 (2003: HK$35,290,000) and on the weighted average number of 2,199,224,328 (2003: 1,640,633,346) shares in issue during the year. The computation of the diluted loss per share for 2003 and 2004 did not assume the conversion of the convertible bonds since their exercise would result in a decrease in the loss per share from continuing ordinary operations. The effect of share options is excluded from the calculation of the diluted loss per share since their exercise would result in a decrease in the loss per share from continuing ordinary operations.